PP137: A prospective study of 38 cases major salivary gland lymphoepithelial carcinoma treated by surgical resection and extensive field postoperative radiotherapy: A single institution experience

Abstract

To analyze our treatment experience of patients with major salivary gland Lymphoepithelial carcinoma who had undergone surgical resection and extensive field Postoperative Radiotherapy (PORT). Patients with primary lymphoepithelial carcinoma in major salivary gland treated at our department between September 2005 and December 2011 were analyzed. All the patients were definitive diagnosed based on histopathology after excluding nasopharyngeal carcinoma. They were all treated with surgical resection followed by extensive field PORT. We delivered a total median dose of 60 Gy,54 Gy at 2 Gy per fraction to the tumor bed and the elective neck lymphatics, respectively. The relevant clinical characteristics were accessed by univariate and multivariate analysis. Our primary endpoint was disease-free survival (DFS) and it was calculated using the Kaplan–Meier method. A total of 38 patients were enrolled in our group. Among them TNM stage distribution was: stage I in seven patients, stage II in nine patients, stage III in six patients, stage IV in 16 patients. The median follow-up period was 37.5 months (range, 11–84 months). The 1-and 3-years estimate of disease-free survival were 94.6% and 91.1%, respectively. During the period, only one patient died. We found the number of positive lymph node was correlated with the DFS by multivariate analysis. The status of nerve invasion was correlated with the DFS by univariate analysis. Patients with SGLEC treated with surgery plus PORT achieved relatively good survival. The worse prognosis was related to the positive lymph node number. The role of adjuvant systemic or targeted therapy in patients with positive lymph node should be investigated in future trials.